Patient characteristics
. | Baseline expression of 5′ GR promoter transcripts . | Effect of GCs on 5′ GR promoter and 3′ GR transcript levels . |
|---|---|---|
| N | 48 | 22 |
| Sex | ||
| Male | 28 | 12 |
| Female | 20 | 10 |
| Age | ||
| 1-9 y | 36 | 11 |
| 10 y and older | 12 | 11 |
| Immunophenotype | ||
| Precursor B-ALL | 36 | 9 |
| T-ALL | 12 | 13 |
| WBC | ||
| Less than 50 × 109 | 18 | 3 |
| 50 × 109 or more | 30 | 19 |
| In vitro prednisolone toxicity | ||
| Sensitive | 24 | 12 |
| Resistant | 24 | 10 |
. | Baseline expression of 5′ GR promoter transcripts . | Effect of GCs on 5′ GR promoter and 3′ GR transcript levels . |
|---|---|---|
| N | 48 | 22 |
| Sex | ||
| Male | 28 | 12 |
| Female | 20 | 10 |
| Age | ||
| 1-9 y | 36 | 11 |
| 10 y and older | 12 | 11 |
| Immunophenotype | ||
| Precursor B-ALL | 36 | 9 |
| T-ALL | 12 | 13 |
| WBC | ||
| Less than 50 × 109 | 18 | 3 |
| 50 × 109 or more | 30 | 19 |
| In vitro prednisolone toxicity | ||
| Sensitive | 24 | 12 |
| Resistant | 24 | 10 |